Pitfalls of Autoimmune Serologic Testing: A Practical Summary for Primary Care Nurse Practitioners

 

Pitfalls of Autoimmune Serologic Testing

A Practical Summary for Primary Care Nurse Practitioners

Based on: Bellocchi C, Beretta L, Montano N. European Journal of Internal Medicine (2026)

 

⚠️  CORE PRINCIPLE Autoimmune serologic markers are a supporting tool—not a standalone diagnostic test. Always interpret results within the clinical context: history, physical examination, and symptom pattern. Testing should be driven by clinical suspicion, not used for screening in the general population.

1. ANA Testing: Where It All Starts

Antinuclear antibodies (ANA) by indirect immunofluorescence (IIF) on HEp-2 cells remain the first-line screening test when a connective tissue disease (CTD) is suspected.

Key Points for Practice

•       Titer ≥1:160 is the threshold for a clinically meaningful positive in most contexts.

•       For SLE specifically, ANA ≥1:80 meets the entry criterion per 2019 EULAR/ACR criteria.

•       10–20% of healthy individuals are ANA positive—this is usually a normal finding.

•       ANA can be positive due to medications, infections, or malignancy.

•       Do NOT repeat ANA once a CTD is diagnosed—titer does not track with disease activity.

•       The fluorescence pattern matters: homogeneous (think anti-dsDNA/SLE), speckled (less specific), nucleolar (think SSc or myositis), centromere (highly specific for SSc), dense fine speckled/DFS70 (in isolation, argues against CTD).

•       Don’t forget thyroid antibodies (anti-TPO, anti-thyroglobulin)—they may be the sole explanation for ANA positivity, especially with a speckled or homogeneous pattern.

2. ENA Panel and Anti-dsDNA

Extractable Nuclear Antigen (ENA) testing is a second-line test. The standard panel includes anti-SSA/Ro, SSB/La, RNP, Scl-70, Jo-1, and Sm antibodies.

When to Order

•       ANA positive at ≥1:160, OR

•       ANA negative but strong clinical suspicion for a systemic autoimmune disease

Specialized panels (myositis-specific, scleroderma-specific, liver-specific) can be requested at specialized centers when the standard panel is negative but suspicion persists.

Anti-dsDNA

•       Highly specific for SLE; the most heavily weighted immunologic criterion in the 2019 SLE classification.

•       Anti-ssDNA is non-specific and not used diagnostically—always order anti-dsDNA.

•       Positive ELISA results should be confirmed by IIF (Crithidia luciliae) for greater specificity.

•       Unlike ANA/ENA, anti-dsDNA levels may fluctuate with SLE disease activity.

3. Rheumatoid Arthritis Markers

ACPA (Anti-Citrullinated Protein Antibodies)

•       Highly specific for RA; may be positive years before symptom onset.

•       Included in the 2010 ACR/EULAR RA classification criteria.

•       Smoking induces citrullination in the lungs—a recognized risk factor for seropositive RA.

Rheumatoid Factor (RF)

•       NOT specific for RA: positive in Sjögren’s (75–90%), HCV, TB, syphilis, and healthy elderly.

•       High RF titers in RA correlate with more severe/erosive disease and extra-articular manifestations.

•       Low RF does not necessarily mean remission—RF does not always track with disease activity.

4. Additional Markers to Know

Complement (C3 and C4)

Low levels suggest complement consumption, classically seen in active SLE. Low C3 is more specific for lupus nephritis; low C4 may point to cryoglobulinemia or hereditary angioedema. Serial trends over time are far more informative than a single measurement. Be aware of SACQ SLE—where serologic abnormalities persist without clinical disease activity (30–50% may eventually flare, but isolated serologic changes alone should not trigger treatment changes).

CPK

Elevated CPK is frequently accompanied by elevated AST. When transaminases are high without clear liver disease, always check CPK—the elevation may reflect muscle injury, not hepatic pathology. Consider inflammatory myopathy (polymyositis/dermatomyositis) in the differential.

CRP and ESR

CRP rises rapidly (6–8 hours) and is more specific for acute inflammation. ESR rises slowly (24–48 hours) and is influenced by age, anemia, and pregnancy. Isolated elevation of either marker, without supporting clinical features, should not automatically trigger rheumatology referral.

Urinalysis

A cost-effective, essential screen for renal involvement in CTDs and vasculitis. Check sediment for protein, RBCs, WBCs, and casts. The urine protein/creatinine ratio helps quantify proteinuria. Always order when a CTD patient presents with new-onset edema.

Serum Protein Electrophoresis

Polyclonal gammopathy (increased gamma globulins) may suggest chronic infection or autoimmune disease. A monoclonal spike suggests clonal proliferation (e.g., MGUS) and may warrant hematology evaluation. Monoclonal gammopathy can coexist with autoimmune disease.

Leukopenia/Thrombocytopenia

Lymphopenia is commonly associated with SLE and Sjögren’s. Thrombocytopenia in a CTD context raises consideration for ITP, antiphospholipid syndrome, or TTP. Also consider medication-induced cytopenias (methotrexate, azathioprine, mycophenolate, IL-6 inhibitors).

 

5. Common Pitfalls at a Glance

Marker	Pitfalls to Remember
ANA	10–20% of healthy individuals test positive; titers <1:160 generally negative; can be positive from drugs, infections, cancer; thyroid antibodies (anti-TPO, anti-TG) may be the sole cause of ANA positivity; no need to repeat ANA once a CTD is diagnosed—titer does not correlate with disease severity
ENA Panel	Only order after ANA ≥1:160 (or if ANA negative with strong clinical suspicion); positive ENA does not always equal autoimmune disease; sensitivity varies between commercial assay platforms; specialized panels exist (myositis, scleroderma, liver-specific)
Anti-dsDNA	Highly specific for SLE; rarely positive in other autoimmune diseases; anti-ssDNA is non-specific and NOT used diagnostically; confirm positive ELISA results with IIF on Crithidia luciliae; levels may fluctuate with disease activity
ACPA	Highly specific for RA; can be present years before clinical onset; may be positive even when ACR/EULAR criteria are not yet met; smoking is a recognized risk factor for ACPA-positive RA
RF	Not specific for RA—found in 75–90% of Sjögren’s patients; can occur in HCV, TB, syphilis; positive in healthy individuals >60–65 years; does not always correlate with RA disease activity; high titers associated with more severe/erosive disease
C3 and C4	Low levels indicate complement consumption (classic: SLE activity); low C3 more specific for lupus nephritis; low C4 may indicate cryoglobulinemia or hereditary angioedema; serial trends are more informative than single values; beware SACQ SLE (serologically active, clinically quiescent)
CPK	Elevated CPK often accompanied by elevated AST—do not assume liver disease; check CPK when transaminases are elevated without clear hepatic cause; may indicate inflammatory myopathy (polymyositis/dermatomyositis)
CRP/ESR	CRP rises within 6–8 hours (more specific for acute inflammation); ESR rises over 24–48 hours (less specific; affected by age, anemia, pregnancy); isolated elevation without clinical signs should not trigger rheumatology referral automatically
Urinalysis	Cost-effective screening for renal involvement in CTDs/vasculitis; check for protein, RBCs, WBCs, and casts in sediment; urine protein/creatinine ratio quantifies proteinuria; always obtain when a CTD patient presents with new edema

 

6. Clinical Screening Questions Before Ordering Labs

The article proposes that one or more affirmative answers to these targeted questions should prompt ANA testing (for CTD suspicion) or RF/ACPA testing (for arthritic symptoms):

1.     Family history of systemic autoimmune disease (ask broadly—including extended family)?

2.     Raynaud’s phenomenon (color changes in fingers with temperature exposure)?

3.     History of pleurisy or pericarditis?

4.     Unexplained low-grade fever for several weeks?

5.     Recurrent major oral or genital aphthosis?

6.     Photosensitivity or facial/skin erythema requiring dermatology evaluation?

7.     Joint pain, swelling, or morning stiffness (>30 minutes suggests inflammatory arthritis)?

8.     Recurrent dry eyes or dry mouth?

9.     Swollen parotid or submandibular glands?

10.  Upper or lower extremity weakness?

11.  History of thrombosis?

12.  Recurrent spontaneous miscarriages, fetal loss, or placental complications?

13.  History of psoriasis, IBD, uveitis, or recent infections (for arthritic presentations)?

 

7. Diagnostic Workflow Summary

For Suspected CTD

1.     Clinical screening questions → if positive, order ANA by IIF

2.     If ANA ≥1:160: evaluate the pattern, then order standard ENA panel, anti-dsDNA, C3/C4, anti-TPO/anti-TG, CBC, renal/liver function, SPEP, CPK, urinalysis

3.     If ANA <1:160 but strong clinical suspicion: still consider ENA and proceed based on clinical judgment

4.     Refer to rheumatology with results in hand

For Suspected RA / Arthritic Symptoms

5.     Characterize joint symptoms: location, symmetry, morning stiffness duration, swelling vs. edema

6.     Order RF, ACPA, CRP, ESR as initial workup

7.     If clinical suspicion persists (± RF/ACPA positivity): add ANA, ENA, and broader workup

8.     Refer to rheumatology—seronegative RA exists, and arthritic symptoms may indicate CTDs, reactive arthritis, psoriatic arthritis, or IBD-associated arthritis

 

BOTTOM LINE FOR NPs Ask the right clinical questions first. Order labs based on clinical suspicion—not as a screening tool. Know the common pitfalls (especially false-positive ANA, non-specific RF, and the importance of thyroid antibodies). Send the patient to rheumatology with at least basic labs completed and the clinical question clearly framed.

 

Reference: Bellocchi C, Beretta L, Montano N. Pitfalls of autoimmune serological markers and practical diagnostic workflows in connective tissue diseases and rheumatoid arthritis. Eur J Intern Med. 2026. doi:10.1016/j.ejim.2026.106763